https://www.gosh.nhs.uk/news/new-commercial-agreement-for-gene-therapy-at-gosh/
New commercial agreement for gene therapy at GOSH
16 Mar 2023, 9:57 a.m.
Great Ormond Street Hospital for Children (GOSH) and Leucid Bio have entered a new commercial agreement to manufacture a gene therapy product.
Gene and cell therapies are the cutting-edge in clinical research for cancer treatments. They hold promise to offer personalised cancer treatments, including for rare forms that sadly affect children and young people. This year, GOSH opened new facilities for manufacturing gene and cell therapies. These facilities have increased our capacity to support development of cell and gene therapies from the very start in discovery research to clinical trials where therapies are tested in patients.
A new agreement with GOSH and Leucid Bio
In a new agreement, GOSH will work with Leucid Bio, a biotechnology company, at the state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children and provide quality assurance services required for manufacture of their gene therapy product, called LEU011.
LEU011 is a type of CAR T-cell therapy which reprogrammes these immune cells to recognise and destroy cancer cells. The company’s therapy has a particular structure on the cell surface that has been shown through early-stage research to work more effectively at targeting cancers than other types of CAR T-cell therapies.
Leucid Bio will submit for clinical trial approvals to trial LEU011, a type of gene therapy product over the next few months. In this first trial for patients, they hope to show that LEU011 improves outcomes and can save the lives of patients with solid tumours and blood cancers.
At Great Ormond Street Hospital, we see children with the most rare and complex cancers. There have been incredible strides forward in the treatment that we can offer, however, sadly for many these still don’t work. Gene therapies offer hope for better, and potentially curative treatments which is why we’re excited to support innovation in gene therapies through access to these highly specialist and unique facilities.“
We are extremely pleased to enter this first of its kind collaboration with GOSH to manufacture our lead asset, LEU011, for use in human studies. Additionally, we are pleased to have started a process with GOSH to examine the feasibility of applying our approach in the paediatric setting where there remains a great unmet need for new therapies.”
More information about CAR T-cell therapy
Five GOSH clinicians recognised with professorial appointments at UCL
Five clinician researchers from GOSH have been promoted to professor by University College London (UCL), recognising their outstanding contributions to research, innovation and child health.
From staff idea to global innovation: Taking the next step towards improving patient safety
A simple idea developed by a GOSH clinician has secured a commercial partner.
Four research projects receive funding to improve understanding and treatment of childhood cancer
Researchers at Great Ormond Street Hospital (GOSH) and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) have received funding from The Little Princess Trust for four childhood cancer research projects.
New study brings hope for children with rare life-threatening kidney disease
New research funded by Great Ormond Street Hospital Charity (GOSH Charity), LifeArc and Kidney Research UK has taken an important step towards developing a new treatment for serious genetic kidney diseases affecting children.